Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
$2.50
$2.71
$2.07
$4.20
$80.49M0.4389,620 shs115,440 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.04
+3.1%
$1.58
$1.11
$17.88
$39.77M1.46716,940 shs243,892 shs
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$2.55
+8.5%
$2.69
$2.12
$5.80
$253.29M2.021.52 million shs1.39 million shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.43
+1.4%
$1.43
$1.12
$2.55
$70.14M0.4638,153 shs14,910 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
0.00%-4.21%-9.42%-18.03%+3.31%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
+2.56%-3.73%+28.77%+16.96%-72.00%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+8.51%+6.69%-11.15%-7.27%-16.67%
MediciNova, Inc. stock logo
MNOV
MediciNova
+1.42%+4.38%-8.33%-13.86%+6.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
2.1088 of 5 stars
3.63.00.00.02.21.70.0
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
1.567 of 5 stars
3.51.00.00.01.11.70.6
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.2739 of 5 stars
3.52.00.00.02.00.00.0
MediciNova, Inc. stock logo
MNOV
MediciNova
1.4036 of 5 stars
3.52.00.00.01.60.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00260.00% Upside
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$34.751,602.60% Upside
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.67318.30% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.00
Buy$9.00529.37% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ANIX, AQST, and MNOV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $17.00
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/9/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/26/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/25/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/21/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
3/14/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/10/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/7/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$7.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
$210K383.30N/AN/A$0.59 per share4.24
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A($0.73) per shareN/A
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$54.23M4.67N/AN/A($1.59) per share-1.60
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M70.14N/AN/A$1.07 per share1.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.39N/AN/AN/A-58.55%-53.29%6/3/2025 (Estimated)
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$56.20M-$2.16N/AN/AN/AN/AN/A-311.00%8/13/2025 (Estimated)
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$7.87M-$0.59N/AN/AN/A-59.75%N/A-33.96%8/5/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$8.56M-$0.23N/AN/AN/AN/A-19.66%-18.63%8/14/2025 (Estimated)

Latest ANVS, ANIX, AQST, and MNOV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2025Q2 2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$0.10N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
3/21/2025Q4 2024
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.38-$0.43-$0.05-$0.43N/AN/A
3/11/2025Q1 2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$0.10-$0.10N/A-$0.10N/AN/A
3/5/2025Q4 2024
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
N/A
8.54
8.54
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
2.66
2.66
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
6.37
5.91
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
13.88
16.66

Institutional Ownership

CompanyInstitutional Ownership
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
29.13%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
25.30%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
8.35%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
532.20 million24.05 millionOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million9.64 millionOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.33 million84.02 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million41.74 millionOptionable

Recent News About These Companies

MediciNova Inc.
MediciNova provides update in letter to stockholders
MediciNova granted Notice of Allowance for MN-001 patent by USPTO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$2.50 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.52 +0.02 (+0.60%)
As of 05/27/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.04 +0.06 (+3.08%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$2.08 +0.03 (+1.67%)
As of 05/27/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$2.55 +0.20 (+8.51%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.54 -0.01 (-0.59%)
As of 05/27/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.43 +0.02 (+1.42%)
Closing price 05/27/2025 03:57 PM Eastern
Extended Trading
$1.53 +0.10 (+6.99%)
As of 05/27/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.